Fulvestrant (Faslodex®)







Printed: 13/May/2020

Name: Nationality: Gender/Age:			File #: Ht Civil ID: W DOB: BS	
Indication(s): Metastatic breast cancer in postmenopausal women, HR positive. Central line: □ Available □ NA Allergies: □ NKA □ Yes, specify;				
Standard	Protocol:			
DRUG	DO	OSE	ADMINISTRATION	I DAYS
Fulvestra	ant 50	00 mg (Loading dose)	Administer IM slowly over 1–2 injection - one injection into ea	
Fulvestra	ant 50	00 mg (maintenance)	Administer IM slowly over 1–2 injection - one injection into ea	
To be re	epeated ev	very 4 weeks until disease pro	ogression or intolerable toxic	city.
Treatmen	t Descript	tion:		
Cycle	Date	Fulvestrant	Physician	Consultant
C#				
•	ed grade 3 Did it indi Did it indi Did it indi	8/4 toxicities: ☐ None ☐ H icate hospitalization? icate chemo-delay for ≥ 7 days' icate dose reduction? icate G-CSF support?	ematological □ Non-Hemato □ Yes □ No ? □ Yes □ No □ Yes □ No □ Yes □ No	ological